Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin (PsyArXiv, 2023)

Potential use of psilocybin drugs in the treatment of depression. - Śladowska K; Kawalec P; Brzostek T; Pilc A. (2023)

Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J mice - Paul Fletcher; Zhaoxia Li; Xiao Dong Ji; Anh D. Lê (Pharmacology Biochemistry and Behavior, 2023)

Molecular and Medical Aspects of Psychedelics. - Wojtas A; Gołembiowska K. (2023)

Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS) - Munchelou M Gomonit; Britni Skillman; Madeleine J. Swortwood (Journal of Forensic Sciences, 2023)

Application of psilocybin in mental health disorders - Jingxuan Chen (Theoretical and Natural Science, 2023)

Is there credible evidence to assert psilocybin-assisted therapy for depression? - Nogueira GN; Vasconcelos MMA; Souza FGM; Bisol LW. (2023)

Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. - Shah FI; Shehzadi S; Akram F; Haq IU; Javed B; Sabir S; Kazim Y; Ashfaq S. (2023)

Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin - Trevor Steward (Trends in Molecular Medicine, 2023)

Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry - Roman Goff; Morgan Smith; Sabrina Islam; Sue Sisley; J. W. Ferguson; Scott Kuzdzal; Sunil Badal; Arun Kumar; Uma Sreenivasan; Kevin A. Schug (Analytica Chimica Acta, 2023)

Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis - Yvan Beaussant; Elise C. Tarbi; Kabir Nigam; Skye A. Miner; Zachary Sager; Justin J. Sanders; Michael Ljuslin; Benjamin Guérin; Paul Thambi; James A. Tulsky; Manish Agrawal (Cancer, 2023)

Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer. - Thrul J; Kozak Z; Carducci MA; Garcia-Romeu A; Yaden DB. (2023)

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder - Manish Agrawal; William A. Richards; Yvan Beaussant; Sarah Shnayder; Rezvan Ameli; Kimberly Roddy; Norma Stevens; Brian D. Richards; Nick Schor; Heather Honstein; Betsy Jenkins; Mark Bates; et al. (Cancer, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders - Yale University (ClinicalTrials.gov, 2023)

Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue - Gregory Ian Robinson; Dongping Li; Bo Wang; Tahiat Rahman; Marta Gerasymchuk; Darryl Hudson; Olga Kovalchuk; Igor Kovalchuk (Life, 2023)

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms. - McCulloch DE; Lopez JP; Dalla C; Castrén E; Erritzoe D; Frokjaer VG; Lundberg J; Preller KH; Fisher PM; Knudsen GM. (2023)

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats - Jonathan Reinwald; Christian N. Schmitz; Ivan Skorodumov; Martin Kuchař; Wolfgang Weber-Fahr; Rainer Spanagel; Marcus W. Meinhardt (Translational Psychiatry, 2023)

Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms - Conn K; Milton L; Huang K; Munguba H; Ruuska J; Lemus M; Greaves E; Homman-Ludiye J; Oldfield B; Foldi C. (bioRxiv, 2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions. - Brennan W; Kelman AR; Belser AB. (2023)

Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin - Ivana Turek (Medical Writing, 2023)

CHIẾT XUẤT PSILOCIN TỪ NẤM THỨC THẦN LÀM NGUYÊN LIỆU THIẾT LẬP CHUẨN - Nguyên Hà Trần; Đặng Đức Khanh; Phạm Đức Trọng; Nguyễn Xuân Trường (Tạp chí Y học Quân sự, 2023)

Drugs for depressionr. (The Medical letter on drugs and therapeutics, 2023)

The effect of casing and gypsum on the yield and psychoactive tryptamine content of Psilocybe cubensis (Earle) Singer. - Foster K; Morrison I; Tyler M; Delgoda R. (2023)

Statistical diversity distinguishes global states of consciousness - Starkey J; Carhart-Harris RL; Pigorini A; Nobili L; Barrett AB. (bioRxiv, 2023)

Psilocybin in Bipolar II Study Provides Preliminary Data on Safety - David B. Yaden; Natalie Gukasyan; Sandeep M. Nayak (JAMA Psychiatry, 2023)

Flies on ’Shrooms: Studying the Psychotherapeutic Potential of Psilocybin using Drosophila - Nicoletta Faraone (American Entomologist, 2023)

Preclinical models of treatment-resistant depression: challenges and perspectives. - Kolasa M; Faron-Górecka A (Pharmacological reports: PR, 2023)

Mindfulness meditation and psychedelics: potential synergies and commonalities. - Holas P; Kamińska J (Pharmacological reports: PR, 2023)

Psilocybin's Erasure of EGO - Gary Ahlskog (The Psychoanalytic Review, 2023)

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings - Christopher R. Nicholas; David Horton; Julia Malicki; Amelia Baltes; Paul R. Hutson; Randall Brown (Psychedelic Medicine, 2023)

Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain - Nicholas Kolbman; Tiecheng Liu; Peter R. Guzzo; Jim Gilligan; George A. Mashour; Giancarlo Vanini; Dinesh Pal (Current Biology, 2023)

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. - Duan W; Cao D; Wang S; Cheng J. (2023)

Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials. - Wang SM; Kim S; Choi WS; Lim HK; Woo YS; Pae CU; Bahk WM. (2023)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD). - Apex Labs Ltd. (ClinicalTrials.gov, 2023)

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds - Adam Waldbillig; Maria Baranova; Sarah Neumann; Jonathan Andrade; Sharan Sidhu (Frontiers in Fungal Biology, 2023)

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (2023)

Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis - George Danias; Jacob M. Appel (JMIR Formative Research, 2023)

Psilocybin shows promise for treating eating disorders, but more controlled research is needed - Elena PhD (2023)

[Feeling unwell after eating a piece of chocolate]. - van der Schuur-Saleem R; Visser E; Robben H; Zwols M; den Besten-Berthololee D. (2023)

A Brief Historical Overview of Psychedelic Research. - Geyer MA. (2023)

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach - McAlpine R; Krajnović K; Khan M; Morometescu L; Simonsson O; Sacchet M; Kamboj S. (PsyArXiv, 2023)

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach (PsyArXiv, 2023)

Psilocybin therapy to reduce depression following a terminal diagnosis - Elizabeth Boudreau; Krissa Orlowski (JAAPA, 2023)

Drug-drug interactions involving classic psychedelics: A systematic review. - Halman A; Kong G; Sarris J; Perkins D. (2023)

Wood-loving magic mushrooms from Australia are saprotrophic invaders in the northern hemisphere - McTaggart A; Scarlett K; Slot J; Barlow C; Appleyard C; Gardiner D; Fechner N; Tilden J; Hass D; Voogelbreinder S; Lording W; Lloyd R; et al. (Authorea Preprints, 2023)

Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. - Hovmand OR; Poulsen ED; Arnfred S. (2023)

Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. - Hernandez-Leon A; Escamilla-Orozco RI; Tabal-Robles AR; Martínez-Vargas D; Romero-Bautista L; Escamilla-Soto G; González-Romero OS; Torres-Valencia M; González-Trujano ME. (2023)

Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. - Bahji A; Lunsky I; Gutierrez G; Vazquez G. (2023)

The potential use of psilocybin in psychiatry - Kamilė Žalkauskaitė; Justina Kirdeikytė; Vilius Ogenskas (Lithuanian University of Health Sciences, 2023)

Aesthetic Chills Mitigate Maladaptive Cognition In Depression - Schoeller F; Jain A; Adrien V; Maes P; Reggente N. (Research Square, 2023)

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential. - Raj P; Rauniyar S; Sapkale B. (2023)

The psychedelic effects of cannabis: A review of the literature. - Wolinsky D; Barrett FS; Vandrey R. (2023)

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2023)

The entropic heart: Tracking the psychedelic state via heart rate dynamics - Rosas FE; Mediano PA; Timmermann C; Luppi AI; Candia-Rivera D; Abbasi-Asl R; Gazzaley A; Kringelbach ML; Muthukumaraswamy S; Bor D; Garfinkel S; Carhart-Harris RL. (bioRxiv, 2023)

Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. - Heresco-Levy U; Lerer B. (2023)

Pharmacists’ perspectives on psilocybin in Canada - Elizabeth Sugiarto; Rebecca Leung; Jamie Yuen (JAPhA Practice Innovations, 2023)

Investigation of the structure, stability, and relative solubility of psilocybin in water and pure organic solvents: A molecular simulation study - Lucas A. Paul; Cyril T. Namba-Nzanguim; Aidani Telesphory; Jehoshaphat Oppong Mensah; Denis Mteremko; Rene Costa; Saidi Mohamedi Katundu; Lucas P. Kwiyukwa; Naserian Daniel Kambaine; Julius Juvenary; Sixberth Mlowe; Geradius Deogratias; et al. (Journal of Molecular Liquids, 2023)

Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. - Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A. (2023)

The possible place for psychedelics in pharmacotherapy of mental disorders. - Wojtas A. (2023)

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. - Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ. (2023)

Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions - Ana-Maria Iorgu; Andrei-Nicolae Vasilescu; Natascha Pfeiffer; Rainer Spanagel; Anne Stephanie Mallien; Dragoš Inta; Peter Gass (European Archives of Psychiatry and Clinical Neuroscience, 2023)

LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain. - Van Der Walt J; Parker R. (2023)

A "Magic Mushroom" Multi-Product Sesquiterpene Synthase. - Schäfer E; Seibold PS; Bartram S; Trottmann F; Haensch VG; Gressler M; Chadeayne AR; Hertweck C; O'Connor SE; Hoffmeister D (Chembiochem: a European journal of chemical biology, 2023)

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. - Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST. (2023)

Cultivation, chemistry, and genome of Psilocybe zapotecorum - Miller DR; Jacobs JT; Rockefeller A; Singer H; Bollinger IM; Conway J; Slot JC; Cliffel DE. (bioRxiv, 2023)

The remarkable reimagining of psilocybin - Crist N. Filer (Natural Product Research, 2023)

Anxiolytic behavior accompanied by the alteration of the intestinal bacteriome during psilocybin treatment - Emese Prandovszky; Zachary A. Cordner; Hua Liu; Megan Pedicini; Lindsey Macias; Kellie L. Tamashiro; Robert H. Yolken (Brain Behavior and Immunity, 2023)

Peak Experiences: Lessons Learned from a Feasibility Study of Psilocybin-assisted Therapy for Demoralization in Patients Receiving Hospice Care - Roxanne Sholevar (Journal of the Academy of Consultation-Liaison Psychiatry, 2023)

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception - Muller S; Cavanna F; de la Fuente L; Bruno N; D’Amelio TA; Pallavicini C; Tagliazucchi E. (bioRxiv, 2023)

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action. - Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A. (2023)

The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies - Kurt Stocker; Matthias Hartmann; Laura Ley; A. Becker; Friederike Holze; Matthias E. Liechti (Journal of Psychopharmacology, 2023)

Single dose of psilocybin improves depressive symptoms in Phase 2 study (The Brown University Psychopharmacology Update, 2023)

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. - Kaminski D; Reinert JP. (2023)

A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics. - Banushi B; Polito V (Biology, 2023)

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues - Kratina S; Lo C; Schwartz R; Strike C; Jopling S; Nayfeh A; Rush B. (PsyArXiv, 2023)

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues (PsyArXiv, 2023)

Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol - Natasha Biscoe; Amanda Bonson; Max Slavin; Walter Busuttil; Deirdre MacManus; Andrew T. Cox; Dominic Murphy (European Journal of Trauma & Dissociation, 2023)

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice. - Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maeda K; González-Maeso J; Kitagaki S; et al. (2023)

Cardiovascular safety of psychedelic medicine: current status and future directions. - Wsół A. (2023)

Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms - Rakoczy RJ; Runge GN; Sen AK; Sandoval O; Nguyen Q; Roberts BR; Sciortino JH; Gibbons WJ; Friedberg LM; Andrew Jones J; McMurray MS. (bioRxiv, 2023)

Is psilocybin effective for treatment of depression? - Lucia Carbajal; Tessa E. Moore; R. H. Barry Sample; Joseph Nelson (Evidence-Based Practice, 2023)

Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences - Brian Macallan (Religions, 2023)

Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test - Arya Rahbarnia; Zhaoxia Li; Paul Fletcher (Psychopharmacology, 2023)

Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats - Natalia Malikowska-Racia; Maciej Koniewski; Joanna Gołębiowska; Piotr Popik (Journal of Psychopharmacology, 2023)

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review. - Watford T; Masood N. (2023)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use - Mathai DS; Roberts DE; Nayak SM; Sepeda ND; Lehrner A; Johnson M; Lowe MX; Jackson H; Garcia-Romeu A. (PsyArXiv, 2023)

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences - Nathalie M. Rieser; Ladina P Gubser; Flora Moujaes; Patricia Duerler; Candace R. Lewis; Lars Michels; Franz X. Vollenweider; Katrin H. Preller (Scientific Reports, 2023)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use (PsyArXiv, 2023)

Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders? - Ian B. Hickie; Allan H. Young; F. Markus Leweke (Research Directions Depression, 2023)

Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin - Payman Baharmand; Amardeep Kambo (BCIT Environmental Public Health Journal, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II - Yale University (ClinicalTrials.gov, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I - Yale University (ClinicalTrials.gov, 2023)

Novel treatments for anorexia nervosa: Insights from neuroplasticity research. - Keeler JL; Kan C; Treasure J; Himmerich H. (2023)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study - Enriquez-Geppert S; Krc J; O'Higgins F; Lietz MP. (PsyArXiv, 2023)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study (PsyArXiv, 2023)

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. - Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD. (2023)

Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and Future - Anna Douglas; Daniel Staas; Anna Hampton; Kylie Burns; F. Suter (Georgetown Scientific Research Journal, 2023)

Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use - Kiffer G. Card; Ashmita Grewal; Kalysha Closson; Gina Martin; Laura Baracaldo; Sandra Allison; Daniel J. Kruger; Zach Walsh (Journal of Psychoactive Drugs, 2023)

Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology - Shinozuka K; Jerotic K; Mediano P; Zhao AT; Preller KH; Carhart-Harris R; Kringelbach ML. (bioRxiv, 2023)

Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results. - Linguiti S; Vogel JW; Sydnor VJ; Pines A; Wellman N; Basbaum A; Eickhoff CR; Eickhoff SB; Edwards RR; Larsen B; McKinstry-Wu A; Scott JC; et al. (2023)

Psilocybin shows promising results in subjects continuing to use an antidepressant (The Brown University Psychopharmacology Update, 2023)

UNRAVELLING THE ROLE OF5-HT2AR ACTIVATION IN THE LONG-LASTING BEHAVIORAL EFFECTS OF PSILOCYBIN - Chloé Galipeau; Miguel Farinha-Ferreira; Jean-Charles Mariani; Samuel Diebolt; Louis Barthe; Renata Santos; Zsolt Lenkei; Ana M. Sebastião (IBRO Neuroscience Reports, 2023)

PSILOCYBIN EXERTS ANTIDEPRESSANT EFFECTS IN A CHRONIC UNPREDICTABLE MILD STRESS (CUMS) ANIMAL MODEL - Ines Erkizia-Santamaría; J. Javier Meana; Igor Horrillo; Jorge E. Ortega (IBRO Neuroscience Reports, 2023)

DOES THE PHENOMENOLOGY OF THE PSILOCYBIN EXPERIENCE PREDICT LONG-TERM EFFECTS ON MOOD AND WELL-BEING IN HEALTHY VOLUNTEERS? - Tomáš Páleníček; Tereza Klučková; M. Nikolič; Čestmír Vejmola; Filip Tylš; Vojtěch Viktorin; Jiřı́ Horáček; Martin Brunovský (IBRO Neuroscience Reports, 2023)

6.3 Psilocybin Therapy for the Treatment of Young Adults With Anorexia Nervosa: State of the Research - Amanda E. Downey (Journal of the American Academy of Child & Adolescent Psychiatry, 2023)

CROSS-SPECIES EVIDENCE FOR PSILOCIN-INDUCED VISUAL HALLUCINATIONS: RATS PERCEIVE QUALITATIVELY SIMILAR CHANGES AS HUMANS - Čestmír Vejmola; Kateřina Syrová; Klára Šíchová; Vlastimil Koudelka; Jan Hubený; Tereza Klučková; M. Nikolič; Eduard Kelemen; Tomáš Páleníček (IBRO Neuroscience Reports, 2023)

Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis. - Gold ND; Mallard AJ; Hermann JC; Zeifman RJ; Pagni BA; Bogenschutz MP; Ross S (Journal of palliative medicine, 2023)

Use of Psychedelics for Pain: A Scoping Review. - Goel A; Rai Y; Sivadas S; Diep C; Clarke H; Shanthanna H; Ladha KS. (2023)

Neuroimaging in psychedelic drug development: past, present, and future. - Wall MB; Harding R; Zafar R; Rabiner EA; Nutt DJ; Erritzoe D. (2023)

Psilocybin kann offenbar Depressionen lindern - Thomas Müller (MMW - Fortschritte der Medizin, 2023)

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence - University of New Mexico (ClinicalTrials.gov, 2023)

A suite of engineered mice for interrogating psychedelic drug actions - Chiu Y; Deutch AY; Wang W; Schmitz GP; Huang KL; Kocak DD; Llorach P; Bowyer K; Liu B; Sciaky N; Hua K; Chen C; et al. (bioRxiv, 2023)

Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala - Thomas J. Kelly; Emma M. Bonniwell; Lianwei Mu; Xiaojie Liu; Ying Hu; Vladislav Friedman; Hao Yu; Wantang Su; John D. McCorvy; Qing-song Liu (Neuropsychopharmacology, 2023)

Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study - Wojtas A; Bysiek A; Wawrzczak-Bargiela A; Maćkowiak M; Gołembiowska K. (Preprints.org, 2023)

Psychedelic 5-HT2A receptor agonism: neuronal signatures and altered neurovascular coupling. - Padawer-Curry JA; Krentzman OJ; Kuo C; Wang X; Bice AR; Nicol GE; Snyder AZ; Siegel JS; McCall JG; Bauer AQ. (bioRxiv, 2023)

Expectancies for Subjective and Antidepressant Effects in Psilocybin Users - Mitch Earleywine; Maha N. Mian; Joseph A. De Leo (Journal of Humanistic Psychology, 2023)

Manic episode following psilocybin use in a man with bipolar II disorder: a case report - Haniya J. Halim; Bradley G. Burk; Rachel E. Fargason; Badari Birur (Frontiers in Psychiatry, 2023)

Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators - Milan Scheidegger (ClinicalTrials.gov, 2023)

Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder - University of Zurich (ClinicalTrials.gov, 2023)

Self-perception and self-recognition while looking in the mirror on psilocybin - Sam Elias; Stephanie Spivak; Alexa Alverez; Alejandro Gili Olivares; Maria Ferrol; Julian Paul Keenan (Journal of Psychedelic Studies, 2023)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey - Sandeep M. Nayak; Hillary Jackson; Nathan D. Sepeda; David S. Mathai; Sara So; Abigail Yaffe; Hadi Zaki; Trey Brasher; Matthew X. Lowe; Del R. P. Jolly; Frederick S. Barrett; Roland R. Griffiths; et al. (Frontiers in Psychiatry, 2023)

Dynamic Functional Hyperconnectivity after Psilocybin Intake is Primarily Associated with Oceanic Boundlessness - Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A. (bioRxiv, 2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder - Keith G. Heinzerling; Karina Sergi; Micah Linton; Rhianna Rich; Brittany Youssef; Inez Bentancourt; Jennifer E. Bramen; Prabha Siddarth; L. Schwartzberg; Daniel F. Kelly (Frontiers in Psychiatry, 2023)

Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential. - Kargbo RB. (2023)

Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions - Lobe Sciences Ltd. (ClinicalTrials.gov, 2023)

Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin - NM Mahmudul Alam Bhuiya; Robin J. Jacobs; Karina Wang; Yiqun Sun; Brenda Nava; Luke Sampiere; Akhila Yerubandi; Joshua Caballero (Cureus, 2023)

Can a single dose of psilocybin improve cognitive control in functional dissociative seizures? - Julien Chupin; Jorge López-Castromán; Caroline Brière; Fabrício Pereira; Coraline Hingray; Ismaël Conejero (Medical Hypotheses, 2023)

Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations. - Wolfgang AS; Hoge CW. (2023)

Rapid, biochemical tagging of cellular activity history in vivo - Zhang R; Anguiano M; Aarrestad IK; Lin S; Chandra J; Vadde SS; Olson DE; Kim CK. (bioRxiv, 2023)

The zebrafish for preclinical psilocybin research. - Syed OA; Tsang B; Gerlai R. (2023)

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study - Natasha L. Mason; Attila Szabó; Kim P. C. Kuypers; Pablo Mallaroni; R. de la Torre Fornell; Johannes T. Reckweg; Desmond H. Y. Tse; Nadia R. P. W. Hutten; Amanda Feilding; Johannes G. Ramaekers (Brain Behavior and Immunity, 2023)

Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development - Marc J. Weintraub; Jessica Jeffrey; Charles S. Grob; Megan Ichinose; R. Lindsey Bergman; Ziva D. Cooper; David J. Miklowitz (Psychedelic Medicine, 2023)

Potential Benefits of Psilocybin for Lupus Pain: A Case Report - Sofia Audrey B. Gonzales; Christine Alexopoulos; Daniel G. Arkfeld (Current Rheumatology Reviews, 2023)

Psilocybin, escitalopram have comparable effects on personality in patients with depression (The Brown University Psychopharmacology Update, 2023)

Acute effects of psilocybin, LSD, mescaline found to be similar (The Brown University Psychopharmacology Update, 2023)

Comparison of fragrance and flavor components in non-psilocybin and psilocybin mushrooms using vacuum-assisted headspace high-capacity solid-phase microextraction and gas chromatography-mass spectrometry - Shannon L. Thomas; Colton Myers; Kevin A. Schug (Advances in Sample Preparation, 2023)

Psilocybin Use in Palliative Care #464 - Mark D. Sims; John Hendrick (Journal of Palliative Medicine, 2023)

P05-02: Assessment of the CYP450 inhibitory activity of psilocybin, psilocin, LSD, 5-MeO-DMT and mescaline: An in vitro study - A. M. Costa; Mariana Silva-Carvalho; Áurea Madureira-Carvalho; Ricardo Jorge Dinis-Oliveira; D. Dias-da-Silva (Toxicology Letters, 2023)

Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins. - Szigeti B; Phillips LD; Nutt D (British journal of clinical pharmacology, 2023)

Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. - Garakani A; Alexander JL; Sumner CR; Pine JH; Gross LS; Raison CL; Aaronson ST; Baron DA. (2023)

Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy. - Miller M; Rosa WE; Doerner Rinaldi A; Addicott K; Spence D; Beaussant Y (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats - Kat F. Kiilerich; Joe Lorenz; Malthe B. Scharff; Nikolaj Speth; T Brandt; Julia Czurylo; Mengfei Xiong; Naja S. Jessen; Agata Casado-Sainz; Vladimir Shalgunov; Celia Kjærby; Grzegorz Satała; et al. (Molecular Psychiatry, 2023)

Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report. - David W. Lawrence (PubMed, 2023)

Psychedelics for treatment resistant depression: are they game changers? - Kalfas M; Taylor RH; Tsapekos D; Young AH. (2023)

Psilocybin for anorexia nervosa: If it helps, let’s learn how - Evelyn Attia; Joanna Steinglass (Med, 2023)

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. - Herrmann Z; Levin AW; Cole SP; Slabaugh S; Barnett B; Penn A; Jain R; Raison C; Rajanna B; Jain S (Psychedelic medicine (New Rochelle, N.Y.), 2023)

A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond. - Pepe M; Hesami M; de la Cerda KA; Perreault ML; Hsiang T; Jones AMP. (2023)

Psilocybin history, action and reaction: A narrative clinical review. - Sharma P; Nguyen QA; Matthews SJ; Carpenter E; Mathews DB; Patten CA; Hammond CJ. (2023)

Single-Dose Psilocybin Treatment for Major Depressive Disorder - Charles L. Raison; Gerard Sanacora; Joshua Woolley; Keith G. Heinzerling; Boadie W. Dunlop; Randall Brown; Rishi Kakar; Michael Hassman; Rupal Trivedi; Reid Robison; Natalie Gukasyan; Sandeep M. Nayak; et al. (JAMA, 2023)

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD - Alexsandra Kovacevich; Jeremy Weleff; Benjamin Claytor; Brian S. Barnett (Journal of Psychoactive Drugs, 2023)

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers - David S. Mathai; Samantha Hilbert; Nathan D. Sepeda; Justin C. Strickland; Roland R. Griffiths; Albert Garcia-Romeu (Psychedelic Medicine, 2023)

Pharmacology and Therapeutic Effects of Psilocybin - Xuehan Du (Highlights in Science Engineering and Technology, 2023)

Intravenous psilocybin administration attenuates mechanical hypersensitivity in a rat model of chronic pain - Kolbman N; Liu T; Guzzo P; Gilligan JP; Mashour GA; Vanini G; Pal D. (bioRxiv, 2023)

Development and validation of a sensitive LC-MS-MS method to quantify psilocin in authentic oral fluid samples - Marilia Santoro Cardoso; Kelly Francisco da Cunha; Izabelly Geraldes Silva; Taís Regina Fiorentin; Eduardo Geraldo de Campos; José Luiz Costa (Journal of Analytical Toxicology, 2023)

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests - Grant Jones; Maha Al-Suwaidi; Franchesca Castro-Ramirez; Taylor C. McGuire; Patrick Mair; Matthew K. Nock (Frontiers in Psychiatry, 2023)

Psilocybin desynchronizes brain networks - Siegel JS; Subramanian S; Perry D; Kay B; Gordon E; Laumann T; Reneau R; Gratton C; Horan C; Metcalf N; Chacko R; Schweiger J; et al. (medRxiv, 2023)

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders. - Wong S; Yu AY; Fabiano N; Finkelstein O; Pasricha A; Jones BDM; Rosenblat JD; Blumberger DM; Mulsant BH; Husain MI. (2023)

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences - Richard J. Zeifman; Hannes Kettner; Broc A. Pagni; Austin J. Mallard; Daniel E. Roberts; David Erritzøe; Stephen Ross; Robin Carhart-Harris (Scientific Reports, 2023)

Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy - Benjamin M. Ross; James T. Neill (Journal of Psychedelic Studies, 2023)

Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter? - Antonio F. Pagán; Claudia Lex; Jair C. Soares; Thomas D. Meyer (Psychedelic Medicine, 2023)

A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder - Raúl Escamilla; María Eva González-Trujano; Jesús M. González Mariscal; J. Martı́n Torres-Valencia; Héctor Guzmán-González; José Luis Vega; Anja Loizaga-Velder (Journal of Psychoactive Drugs, 2023)

Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy? - Marie Crowe; Jenni Manuel; Dave Carlyle; Cameron Lacey (International Journal of Mental Health Nursing, 2023)

Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study - Robert Gramling; Emily Bennett; Keith Curtis; William A. Richards; Donna M. Rizzo; Francesca Arnoldy; Logan P Hegg; Jon Porter; Heather Honstein; Susanna Pratt; Elise C. Tarbi; Maija Reblin; et al. (Journal of Palliative Medicine, 2023)

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report - Rebecchi K. (PsyArXiv, 2023)

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report (PsyArXiv, 2023)

use of psilocybin in the treatment of psychiatric disorders - review - Justyna Woźniak; Rafał BOGACZ; Magdalena Gaik; Ewa URAM; Inga MAGDA; Karol Womperski; Magdalena OSUCH (Journal of Education Health and Sport, 2023)

A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics - Usona Institute (ClinicalTrials.gov, 2023)

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells. - Robinson GI; Li D; Wang B; Zahoruiko Y; Gerasymchuk M; Hudson D; Kovalchuk O; Kovalchuk I. (2023)

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. - Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R. (2023)

Psilocybin's Emerging Role in Combating Depressive Disorder - Anna Jaremek; Joanna Kępa; Norbert Kandefer; Michał Wyszkowski; Aleksandra Grabarczyk; Anna Pawlak; Sylwia Grad; Małgorzata Gregorek; Paweł Gregorek (Journal of Education Health and Sport, 2023)

“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy - Amanda E. Downey; Maxine Boyd; Anita V. Chaphekar; Joshua Woolley; Marissa Raymond-Flesch (International Journal of Eating Disorders, 2023)

A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression. - Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X (International journal of molecular sciences, 2023)

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. - Perez N; Langlest F; Mallet L; De Pieri M; Sentissi O; Thorens G; Seragnoli F; Zullino D; Kirschner M; Kaiser S; Solmi M; Sabé M. (2023)

The Potential of Psychedelics for the Treatment of Episodic Migraine. - Schindler EAD. (2023)

Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia - Ruzmayuddin Mamat; Rusdi Abd Rashid; Maw Shin Sim; Baharudin Ibrahim; Suzaily Wahab; Azmir Ahmad (Journal of Addictive Diseases, 2023)

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice - N. Jones; Zarmeen Zahid; Sean M. Grady; Ziyad W. Sultan; Zhen Zheng; John A. Razidlo; Matthew I. Banks; Cody J. Wenthur (ACS Pharmacology & Translational Science, 2023)

Psilocybin und Funktionalität bei Depression - Moritz Spangemacher (InFo Neurologie + Psychiatrie, 2023)

Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022. - Jing X; Hoeh NR; Menkes DB. (2023)

Psilocybin for the treatment of anorexia nervosa. - Majić T; Ehrlich S. (2023)

Psychedelic drugs in the treatment of psychiatric disorders. - Ibrahim IB; Videbech P; Straszek SPV. (2023)

On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked - Benjamin A. Korman (Journal of Psychoactive Drugs, 2023)

The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study - Brain; Cognition Discovery Foundation (ClinicalTrials.gov, 2023)

“Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance - Finkelstein C; Soha O; Roy A; Phillipou A; Rossell S. (Research Square, 2023)

An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients. - The Roots to Thrive Society for Psychedelic Therapy (ClinicalTrials.gov, 2023)

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters. - Jahanabadi S; Amiri S; Karkeh-Abadi M; Razmi A. (2023)

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. - Simonsson O; Carlbring P; Carhart-Harris R; Davis AK; Nutt DJ; Griffiths RR; Erritzoe D; Goldberg SB. (2023)

Distinctive Molecular and Metabolic Profiles of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract - Shahar O; Botvinnik A; Shwartz A; Lerer E; Buko A; Hamid E; Kahn D; Guralnick M; Blakolmer K; Wolf G; Lerer L; Lerer B; et al. (Research Square, 2023)

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression - Goodwin G; Marwood L; Mistry S; Nowakowska A; Simmons H; Tsai J; Williams S; Young M; Malievskaia E. (2023)

A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol - Husain M; Blumberger D; Castle D; Kloiber S; Ortiz A; Rosenblat J; Mulsant B. (2023)

Psychedelics for depression: from neurobiology to treatment - Kuypers K. (2023)

Knocking on the Doors of Perception: the role of psilocybin in substance use disorder treatment - Sousa R; Costa L; Brás J; Vaz R; Martins J; Abreu J; Almeida E; Castro N; Andrade R; Cunha N. (2023)

The therapeutic potential of psilocybin in depression resistant to psychotropic drugs - Ramírez González J; Fernández Márquez I; Ferreiro González S; Ruíz E. (2023)

A systematic review to assess the use of psilocybin in the treatment of headaches - Bhanot S; Lin M; Bains S; Monroe A; Tsang V. (2023)

Systematic Review on the Mechanisms of Action of Psilocybin in the Treatment of Depression - Lin M; Lee H; Tsang V; Chai B; Howard A; Uy C; Elefante J. (2023)

Psilocybin as an antidepressant strategy - a review of safety aspects - Zeiss R. (2023)

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUM. - Weiss B; Ginige I; Shannon L; Giribaldi B; Murphy-Beiner A; Murphy R; Baker-Jones M; Martell J; Nutt DJ; Carhart-Harris RL; Erritzoe D. (2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions (PsyArXiv, 2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions - Brennan B; Kelman A; Belser AB. (PsyArXiv, 2023)

Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour - Nkadimeng SM; Hay L; Steinmann CM; Eloff JN. (Research Square, 2023)